Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.
about
The "inherent vice" in the anti-angiogenic theory may cause the highly metastatic cancer to spread more aggressively.Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, ArgentinaAflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.Clinical overview of metronomic chemotherapy in breast cancer.Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach.Microenvironmental regulation of tumour angiogenesis.Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment.Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.Assessing metastasis risk after pre-operative anti-angiogenic therapy.The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.Murine breast cancer mastectomy model that predicts patient outcomes for drug development.The immunomodulatory, antitumor and antimetastatic responses of melanoma-bearing normal and alcoholic mice to sunitinib and ALT-803: a combinatorial treatment approach.Tumor-independent host secretomes induced by angiogenesis and immune-checkpoint inhibitors.
P2860
Q33725650-F0A3F9B0-A197-4D74-9402-5F516DBD6F7EQ36618871-EEDEE67C-353D-49CB-92AD-AA2687EC6D77Q37239002-27894832-E8EB-4134-A315-A77D14C0CD58Q37411781-926B2F3D-AE0B-4A44-A433-81C29DD71B2AQ38560651-8899A625-0FEB-4F41-A4AF-D5B1F8D0BE37Q38824064-5BE9F14C-A487-4D2A-A56C-595ECD08F34BQ39433862-C69A44CB-50EA-441B-928C-A52C8E381434Q40306627-23EC5795-FEA8-4230-AA23-BA8039EA83D8Q41742917-B656A6BA-6080-4A09-820E-43D0FBC3680CQ41884180-F31824A5-04FA-4FCF-A97B-4B1135889695Q44456046-1A1DDA2A-8EB0-4BE1-B134-2AAD1BE1F618Q50099125-0A660577-3108-489C-B3D1-9C23612B5205Q50632502-48E1AF97-11E5-4D06-9880-7042E4877569Q52562886-1DB0CD90-8AF7-479B-BEEF-34B27316F002
P2860
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@ast
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@en
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@nl
type
label
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@ast
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@en
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@nl
prefLabel
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@ast
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@en
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@nl
P2093
P2860
P356
P1476
Neoadjuvant antiangiogenic the ...... and metastatic tumor efficacy.
@en
P2093
Amanda Tracz
Christina R Lee
Christopher Jedeszko
John M Hudson
Kristopher Attwood
Michalis Mastri
Peter Burns
Robert S Kerbel
William R Cruz-Munoz
P2860
P304
P356
10.15252/EMMM.201403989
P50
P577
2014-10-31T00:00:00Z